🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

RecruitingPhase 4Ages 18 Years - 75 YearsFemaleMansoura University
NCT07416968 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg), a medicine taken once a day. The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day. The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits. The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects. Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * OAB symptoms persisting for ≥3 months * OAB Symptom Score (OABSS) \> 5 and urgency sub-score of OABSS ≥ 2 * Ability and willingness to provide informed consent. Exclusion Criteria: * Active urinary tract infection. * Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI * Pelvic organ prolapse stage ≥II according to POP-Q system. * History of pelvic radiation. * History of neurosurgical interventions. * Pregnancy or breastfeeding. * Neuropathic diseases affecting the lower urinary tract. * History of genitourinary malignancy. * Post-void residual urine (PVR) \> 150 ml. * Vesical or lower ureteric stones. * Uncontrolled diabetes mellitus (HbA1c \> 7). * Any psychological or psychiatric disorders. * Contraindications or allergy to the used medications. * History of surgeries in the urinary bladder. * History of pelvic surgeries within 6 months. * Voiding dysfunctions.
💊

What it tests

  • Tadalafil 5 mg
  • Solifenacin 5mg
📍

Where

14 sites
Faculty of medicine, Menofia Univeristy
Shibīn al Kawm, Egypt
Faculty of medicine, Zagazig University
Zagazig, Egypt
Urology and Nephrology Center, Mansoura University
Al Mansurah, Egypt
Faculty of medicine, Tanta University
Tanta, Egypt
faulty of medicine, Tanta Univeristy
Tanta, Egypt
Faculty of medicine, minia university
Al Minyā, Egypt
Faculty of medicine, Alexandria University
Alexandria, Egypt
Faculty of medicine, Aswan university
Aswān, Egypt

…and 6 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy